LANHAM, Md., Nov. 09, 2023 (GLOBE NEWSWIRE) — At the 2023 Annual International Conference on ADHD 2023, the leading experts in attention-deficit/hyperactivity disorder (ADHD) will convene to deliver trusted information about the latest research, treatment options, and practical guidance to members of the ADHD community.

Since the pandemic eased, millions of Americans have had to deal with several drug shortages. For those with ADHD, it’s been an especially difficult year as they and their families have struggled to get through ordinary daily routines. Stephanie Sy has the story.

A recent study published in the Journal of Sleep Research has found that the use of weighted blankets can significantly improve the sleep quality of children diagnosed with Attention Deficit Hyperactivity Disorder (ADHD). These blankets — which are heavier than typical bed covers — have been shown to boost the duration and quality of sleep in the…

In a recent study published in the Journal of Psychiatric Research, researchers describe the relationship between problematic internet use (PIU) and the symptoms of attention deficit hyperactivity disorder (ADHD).

A new study of undergraduate students found that individuals with attention-deficit/hyperactivity (ADHD) disorder were more likely to be evening types compared to individuals without this disorder. Furthermore, individuals with ADHD were more prone to exhibit depressive symptoms. This trend was especially pronounced among evening-type participants. The study was published in the Journal of Sleep Research.

Licensed dosing of stimulants is associated with more reduced symptoms in adults with ADHD than unlicensed dosing, according to a new systematic review meta-analysis led by Luis C. Farhat, MD, of University Hospital in São Paulo, Brazil.[1]

New research from the NIH’s Environmental influences on Child Health Outcomes (ECHO) Program suggests that during the COVID-19 pandemic, some teens with a history of depression, anxiety, autism and ADHD experienced more severe impacts than those without.

On October 30, 2023, Otsuka Pharmaceutical announced positive results from 2 pivotal phase 3 trials of centanafadine, a norepinephrine, dopamine, and serotonin reuptake inhibitor, for adolescents and children with Attention-Deficit/Hyperactivity Disorder (ADHD).[1]

A recent study has found that the link between low fetal growth rate and symptoms of attention-deficit/hyperactivity disorder (ADHD) in children can partially be explained by factors occurring before birth such as pregnancy complications, in addition to familial characteristics such as household income. The findings were published in Research on Child and Adolescent Psychopathology.

Children and young people with attention deficit hyperactivity disorder (ADHD) use health care services twice as often in the two years before their diagnosis, a study by researchers at the University of Nottingham and King’s College London has found.

Extended-release (ER) viloxazine demonstrates continued safety and efficacy with long-term use for attention-deficit/hyperactivity disorder (ADHD) in children and adolescents, according to results presented at the American Academy of Child and Adolescent Psychiatry (AACAP) 2023 Annual Meeting, held from October 23 to 28, 2023 in New York, New York.

Both methylphenidate and atomoxetine improve motor coordination in children with attention-deficit/hyperactivity disorder (ADHD), according to new data presented at the American Academy of Child and Adolescent Psychiatry (AACAP) 2023 Annual Meeting, held from October 23 to 28, 2023 in New York, New York. However, the efficacy of these two medications varies across behavioral and emotional…